Apollo Endosurgery, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Charles S. McKhann
- Full Time Employees
- 202
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- Building 1 Austin TX United States of America 78746
- IPO Date
- Apr 21, 2005
- CIK
- 0001251769
- Website
- apolloendo.com
- Similar Companies
- Business
- Apollo Endosurgery, Inc. develops and commercializes less invasive medical devices for gastrointestinal therapeutic endoscopy and endobariatric procedures, focusing on obesity treatment and closure of gastrointestinal defects; its core products include the OverStitch Endoscopic Suturing System and OverStitch Sx for endoscopic suturing in procedures such as endoscopic sleeve gastroplasty and transoral outlet reduction, the X-Tack Endoscopic HeliX Tacking System for defect closure, the Orbera Intragastric Balloon System for weight management, and the Apollo ESG, Apollo ESG Sx, Apollo REVISE, and Apollo REVISE Sx Systems authorized by the FDA for endoscopic bariatric revision. Founded in 2005 and headquartered in Austin, Texas, the company operates globally in over 70 countries, serving gastroenterologists, bariatric surgeons, and general surgeons through offices in the United States, United Kingdom, Italy, and a manufacturing facility in Costa Rica. Boston Scientific Corporation acquired Apollo Endosurgery in 2023 for approximately $615 million, integrating its endoluminal surgery portfolio to expand capabilities in endoscopy and endobariatrics; prior to the acquisition, Apollo sold its surgical product line including the Lap-Band system to ReShape Lifesciences in 2018 to concentrate on endo-bariatric offerings and received FDA de novo clearance in July 2022 for its ESG and REVISE systems.
Weight Loss Services Market Analysis Report 2024-2030, Featuring Profiles of Atkins Nutritionals, Precor, Apollo Endosurgery, Johnson Health Tech, Life Fitness, iFIT, Torque Fitness and More
APOLLO ENDOSURGERY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apollo Endosurgery, Inc. - APEN
SHAREHOLDER ALERT: Weiss Law Investigates Apollo Endosurgery, Inc.
Buy-rated Boston Scientific's $615 million takeover of Apollo Endosurgery is a positive, says Needham
Apollo Endosurgery Stock Soars on Buyout Buzz
Boston Scientific to acquire Apollo Endosurgery for $615 million in cash
Apollo Endosurgery to be Acquired by Boston Scientific
Boston Scientific Announces Agreement to Acquire Apollo Endosurgery, Inc.
Apollo Endosurgery, Inc. (APEN) Q3 2022 Earnings Call Transcript
Apollo Endosurgery to Report Third Quarter Results on November 1, 2022
Apollo Endosurgery, Inc. (APEN) CEO Chas McKhann on Q2 2022 Results - Earnings Call Transcript
Apollo Endosurgery: Collect Shares At A Discount Following Q2 Earnings
Apollo Endosurgery to Report Second Quarter Results on August 2, 2022
Hot Penny Stocks to Watch Right Now? 3 For Your July List
Apollo Endosurgery's New Obesity Endoscopic Systems Receive FDA Nod
This Analyst Thinks Apollo Endosurgery's Valuation 'Does Not Assign Full Value' - Read Why
Apollo Endosurgery, Inc. (APEN) CEO Chas McKhann on Q1 2022 Results - Earnings Call Transcript
Apollo Endosurgery, Inc. (APEN) Reports Q1 Loss, Tops Revenue Estimates
Apollo Endosurgery to Report First Quarter Results on May 3, 2022
Apollo Endosurgery, Inc. (APEN) CEO Charles McKhann on Q4 2021 Results - Earnings Call Transcript